Omlyclo Purple Book BLA 761399

BLA number
761399
Proprietary names
Omlyclo
Proper names
omalizumab-igec
Applicant
CELLTRION, Inc.
Center
CDER
First observed release
2025-03-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Omlycloomalizumab-igec351(k) Interchangeable75MG/0.5MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2025-03-07
002Omlycloomalizumab-igec351(k) Interchangeable150MG/MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2025-03-07
003Omlycloomalizumab-igec351(k) Interchangeable300MG/2ML (150MG/ML)InjectionSubcutaneousPre-Filled SyringeRxLicensed2025-12-01

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
103976Xolairomalizumab351(a)Rx2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2025-12-01N003Omlyclo351(k) InterchangeableRxCELLTRION, Inc.
2025-03-01N001Omlyclo351(k) InterchangeableRxCELLTRION, Inc.
2025-03-01N002Omlyclo351(k) InterchangeableRxCELLTRION, Inc.

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2025-12-01003Omlyclo351(k) InterchangeableRxLicensed2025-12-01
2025-03-01001Omlyclo351(k) InterchangeableRxLicensed2025-03-07
2025-03-01002Omlyclo351(k) InterchangeableRxLicensed2025-03-07